NDA 021505 · Ucb INC
Keppra
Levetiracetam · Oral
Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jul 15, 2003
Approved uses
6
Original approval plus efficacy supplements
Registered trials
261
71 Phase 3, 26 recruiting
FAERS reports
133,531
111,042 serious, 12,023 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 28, 2026.
KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) KEPPRA is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 ) 1.1 Partial-Onset Seizures KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
Mechanism: The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2019 Supplement 42 · Efficacy LabelLetter
- Dec 16, 2011 Supplement 19 · Efficacy · priority review LabelLetter
- Mar 19, 2007 Supplement 13 · Efficacy LetterLabel
- Aug 15, 2006 Supplement 9 · Efficacy LetterLabel
- Jun 21, 2005 Supplement 7 · Efficacy · priority review LabelLetter
- Jul 15, 2003 Original approval · Type 3 - New Dosage Form Other Important Information from FDAReviewLetter
1 products under this application
- KEPPRA · LEVETIRACETAM 100MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Levetiracetam" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke TrialPivotal-lookingRecruiting
Shanghai East HospitalAcademic, hospital or other
NCT06773364 · 2,423 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 31, 2028
Drug: Levetiracetam · For: Suspected Stroke
Sites: Suzhou, China; Shanghai, China
- Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?Pivotal-lookingStatus unknown
Loyola UniversityAcademic, hospital or other
NCT03054285 · 2,300 participants (planned) · Start Jul 1, 2017 · Primary completion Apr 1, 2020
Drug: Levetiracetam · For: Seizures; Traumatic Brain Injury
Sites: Maywood, Illinois
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00175903 · 1,701 participants · Start Feb 2005 · Primary completion Oct 2007
Drug: Levetiracetam; Carbamazepine Controlled Release (CBZ-CR) and 1 more · For: Epilepsy
Sites: Adelaide, Australia; Bedford Park, Australia; Brisbane, Australia · 229 sites in all
- Pharmacological Management of Seizures Post Traumatic Brain InjuryPivotal-lookingNot yet recruiting
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04573803 · 1,649 participants (planned) · Start Mar 1, 2021 · Primary completion Mar 1, 2026
Drug: Phenytoin Sodium; Levetiracetam · For: Traumatic Brain Injury; Post Traumatic Seizures
UCB PharmaUCB
NCT00630968 · 1,541 participants · Start Aug 2000 · Primary completion Feb 2004
Drug: Levetiracetam (Keppra) · For: Epilepsy
- Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)Pivotal-lookingRecruiting
All India Institute of Medical Sciences, JodhpurGovernment (non-federal)
NCT07072624 · 1,260 participants (planned) · Start Jul 23, 2025 · Primary completion Mar 15, 2027
Drug: Phenytoin; Levetiracetam and 1 more · For: Seizures; Traumatic Brain Injuries; Traumatic Brain Injury (TBI) Patients
Sites: Chandigarh, India; Jodhpur, India; Lucknow, India
- Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic SeizurePivotal-lookingNot yet recruiting
Nebraska Methodist Health SystemAcademic, hospital or other
NCT07220902 · 1,240 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2033
Drug: Levetiracetam; magnesium sulfate · For: Severe Preeclampsia; Eclampsia Preeclampsia
Sites: Omaha, Nebraska
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure15,769
- drug ineffective12,490
- off label use9,614
- fatigue5,592
- somnolence4,201
- epilepsy4,178
- convulsion3,988
- maternal exposure during pregnancy3,813
- fall3,746
- headache3,723
- nausea3,627
- dizziness3,594
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 515 |
| 2005 | 758 |
| 2006 | 908 |
| 2007 | 1,182 |
| 2008 | 1,355 |
| 2009 | 2,201 |
| 2010 | 2,447 |
| 2011 | 3,020 |
| 2012 | 3,954 |
| 2013 | 4,020 |
| 2014 | 4,593 |
| 2015 | 6,309 |
| 2016 | 8,121 |
| 2017 | 7,640 |
| 2018 | 10,346 |
| 2019 | 11,939 |
| 2020 | 9,879 |
| 2021 | 10,064 |
| 2022 | 8,884 |
| 2023 | 9,509 |
| 2024 | 9,901 |
| 2025 | 8,886 |
| 2026 | 7,096 |
Recalls
1 FDA enforcement reports for this application.
Jul 18, 2019 · Class II · Terminated
Failed Dissolution Specifications.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Keppra* (Levetiracetam)
2024 spending
$71.7M
Beneficiaries
5,281
37,683 claims
Per beneficiary
$13,576
$12.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $77,825,801 |
| 2021 | $75,185,539 |
| 2022 | $76,701,477 |
| 2023 | $76,290,254 |
| 2024 | $71,692,904 |
Part B: Keppra* (Levetiracetam*) · HCPCS J1953
2024 spending
$3K
Beneficiaries
135
324 claims
Per beneficiary
$21
2024 ASP limit $0.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,336 |
| 2021 | $2,716 |
| 2022 | $3,121 |
| 2023 | $2,832 |
| 2024 | $2,802 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures.
Pressler RM, Abend NS, Auvin S, et al. · Epilepsia 2023 · Systematic Review, Meta-Analysis
- Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Gilmore EJ, Johnson EL, et al. · Neurocrit Care 2024 · Systematic Review, Practice Guideline
- Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Kapur J, Elm J, Chamberlain JM, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.
Sharpe C, Reiner GE, Davis SL, et al. · Pediatrics 2020 · Clinical Trial, Phase II, Comparative Study
- Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.
Fang T, Valdes E, Frontera JA · Neurocrit Care 2022 · Meta-Analysis, Systematic Review
- Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis.
Medrea I, Cooper P, Lagman-Bartolome AM, et al. · Can J Neurol Sci 2025 · Systematic Review, Meta-Analysis
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.